According to CoinMeta, Shanghai Pharmaceutical announced that its controlling shareholder, Shanghai Shih Group, plans to increase its holdings of the company's H shares within the next 12 months through its wholly-owned subsidiary, Shanghai International. The increase will be carried out via the Hong Kong Stock Exchange system using a centralized bidding method, with the total number of shares to be increased ranging from 11 million to 22 million, not exceeding 1% of the company's voting rights shares. No fixed price range has been set for this increase, and the funds will come from Shanghai International's own resources.